financetom
HAE
financetom
/
Healthcare
/
HAE
All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities
Haemonetics CorporationHAE
USD
- At close
USD
- Until the end
The complete list of US stocks
1D
5D
1M
1Y
5Y
MAX
Overview >
Market Cap
2.97B
Revenue (ttm)
1.37B
Net Income (ttm)
130.07M
Shares Out
50.24M
EPS (ttm)
2.54
PE Ratio
22.97
Forward PE
12.12
Dividend
n/a
Ex-Dividend Date
n/a
Volume
169,260
Open
59.14
Previous Close
59.27
Day's Range
57.96 - 59.46
52-Week Range
55.30 - 97.97
Beta
0.41
Analysts
Strong Buy
Price Target
103.11 (+74.23%)
Earnings Date
May 8, 2025
Description >

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally.

The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360.

It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system.

In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions.

Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot including collagen.

The company sells its products through direct sales force, independent distributors, and sales representatives.

Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

Copyright 2023-2025 - www.financetom.com All Rights Reserved